Increased longevity could be available to billions thanks to the development of a global DNA library, helping researchers understand how longevity works, with investors increasingly interested in backing such schemes. The study was led by Dr David Sinclair, from Imperial College London, and published today in Nature Communications. Several start-ups joined the list of larger drug companies developing the industry in 2018. More start-ups are expected in 2019. New age-delaying properties are being found in existing drugs, while more than 100 new drugs are being tested for similar uses.
Increased longevity could be available to billions thanks to the development of a global DNA library, helping researchers understand how longevity works, with investors increasingly interested in backing such schemes. Recent developments in genome studies and the rapidly falling cost of genetic sequencing could help spread longevity beyond billionaire customers. Several start-ups joined the list of larger drug companies developing the industry in 2018. More start-ups are expected in 2019. New age-delaying properties are being found in existing drugs, while more than 100 new drugs are being tested for similar uses.